Biondvax Pharma Ads (BVXV) 3.60 $BVXV
Professor Shai Ashkenazi Appointed to BiondVax's Scientific Advisory Board
PR Newswire - Wed Sep 07, 8:00AM CDT
BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV, TASE: BVXV), a clinical stage biopharmaceutical company focused on developing and commercializing a vaccine against current and future seasonal and pandemic influenza strains, is pleased to announce the appointment of Professor Shai Ashkenazi to its Scientific Advisory Board (SAB).
BVXV: 3.60 (-0.05)
BiondVax Announces Second Quarter 2016 Financial Results and Update
PR Newswire - Thu Aug 18, 3:07PM CDT
BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV; TASE: BVXV), a clinical stage biopharmaceutical company focused on developing and commercializing a vaccine against current and future seasonal and pandemic influenza strains, today announced its second quarter 2016 financial results ended June 30, 2016 and provided a business update.
BVXV: 3.60 (-0.05)
BiondVax Invited to WHO Influenza Vaccine Meeting
PR Newswire - Wed Aug 10, 7:00AM CDT
BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV, TASE: BVXV) today announced that it has been invited to participate in the 'Eighth WHO meeting on the development of influenza vaccines that induce broadly protective and long-lasting immune responses'. The meeting will be held in Chicago, IL on August 23 and 24, 2016.
BVXV: 3.60 (-0.05)
BiondVax CEO to Present Universal Flu Vaccine Technology at BIO International Convention
PR Newswire - Thu Jun 02, 7:17AM CDT
BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV, TASE: BVXV) announced today that BiondVax's CEO, Dr. Ron Babecoff, will be presenting and participating in a panel discussion at BIO International Convention in San Francisco.
BVXV: 3.60 (-0.05)
BiondVax Announces First Quarter 2016 Financial Results and Update
PR Newswire - Tue May 31, 3:01PM CDT
BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV, TASE: BVXV), a clinical stage biopharmaceutical company focused on developing and commercializing immunomodulation therapies for infectious diseases today announced its first quarter 2016 financial results ended March 31, 2016 and provided a business update. The Company's leading product, M-001, is a universal flu vaccine.
BVXV: 3.60 (-0.05)
BiondVax to Present Tomorrow at Joseph Gunner Pioneers 2016 Conference
PR Newswire - Wed May 04, 8:29AM CDT
BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV, TASE: BVXV) announced today that BiondVax's CEO, Dr. Ron Babecoff, will be attending the Joseph Gunnar Pioneers 2016 conference in New York City.
BVXV: 3.60 (-0.05)
BiondVax Announces Fourth Quarter and Full Year 2015 Financial Results and Update
PR Newswire - Wed Apr 27, 4:18PM CDT
BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV, TASE: BVXV), a clinical stage biopharmaceutical company focused on developing and commercializing immunomodulation therapies for infectious diseases, today announced its fourth quarter and full year financial results ended December 31, 2015 and provided a business update.
BVXV: 3.60 (-0.05)
Biondvax's Universal Flu Vaccine Receives Additional US Patent
PR Newswire - Wed Jan 27, 6:00AM CST
BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV, TASE: BVXV) developer of a Universal Flu Vaccine currently undergoing late-stage 2 clinical trials, announced today that its patent application in the United States titled "Multimeric Multi-Epitope Polypeptides in Improved Seasonal and Pandemic Influenza Vaccines" has completed examination and is allowed for issuance as a patent.
BVXV: 3.60 (-0.05)
BiondVax Receives Approval for a Patent for its Universal Flu Vaccine in Israel
PR Newswire - Mon Dec 21, 7:04AM CST
BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV, TASE: BVXV) which is developing the Universal Flu Vaccine, announced today that its patent application in Israel on the Multimeric Multi-Epitope Polypeptide Influenza Vaccines (a universal flu vaccine), was accepted.
BVXV: 3.60 (-0.05)
BiondVax to Bring Long-Awaited Universal Flu Vaccine to the Market
CNW Group - Thu Dec 03, 9:00AM CST
With various advancements being made in preventative care, cancer treatment, HIV and AIDS research and aging, it's hard to believe that the flu is still a serious health threat. However, influenza, an acute respiratory tract infection, can still prove life threatening for the elderly and those with weak immune systems. A common misconception is that influenza is merely a bad cold. Yet, while the flu may produce similar symptoms to the common cold like coughing or nasal congestion, the World Health Organization reports that 250,000 to 500,000 individuals die annually due to the flu, with the majority of those deaths caused pulmonary and cardiovascular complications. Every year, 36,000 people die in the United States and more than 200,000 are hospitalized due to the flu, along with an annual economic burden of over $25 billion.
BVXV: 3.60 (-0.05)
Patent Approval for BiondVax: BiondVax Receives Approval for Patent in Korea for its Universal Flu Vaccine
PR Newswire - Tue Nov 17, 7:54AM CST
BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV, TASE: BVXV) which is developing the Universal Flu Vaccine, announced today that its main patent on the Multimeric Multi-Epitope Polypeptide Influenza Vaccines family, was granted in Korea.
BVXV: 3.60 (-0.05)
BiondVax Announces Third Quarter 2015 Financial Results and Update
PR Newswire - Mon Nov 09, 6:00AM CST
BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV, TASE: BVXV), a clinical stage biopharmaceutical company focused on developing and commercializing immunomodulation therapies for infectious diseases, today announced its financial results for the third quarter of 2015 and provided a business update.
BVXV: 3.60 (-0.05)
BiondVax Pharmaceuticals Ltd. Selects Cytovance(R) Biologics Inc. for the Manufacturing of M-001 the Universal Flu Vaccine for Phase III Clinical Trials
Marketwired - Tue Nov 03, 4:00AM CST
Cytovance® Biologics, Inc. announced that it has entered into a Development and Manufacturing Agreement for the production of Phase III batches of a universal flu vaccine, M-001, with BiondVax Pharmaceuticals Ltd. (TASE: BVXV) (NASDAQ: BVXV), a biopharmaceutical company, based in Ness Ziona Israel.
BVXV: 3.60 (-0.05)
BiondVax Announces Successful Recruitment of the First Participants in a Phase IIb Clinical Trial in Europe with its Universal Flu Vaccine: Multimeric M-001
PR Newswire - Wed Oct 21, 6:59AM CDT
BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV, TASE: BVXV) announced today that it has successfully recruited the first two participants in this trial, BVX-007. The trial is being conducted in Budapest, Hungary at the St Istvan and St Lazslo Hospital, as well as additional satellite sites in Hungary, together with the partners from the UNISEC European Consortium.
BVXV: 3.60 (-0.05)
BiondVax to Present on October 8 at the Aegis Growth Conference
PR Newswire - Tue Oct 06, 3:30PM CDT
BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV, TASE: BVXV) announced today that BiondVax's CEO, Dr. Ron Babecoff, will participate in the Aegis Growth Conference, taking place at The Encore at Wynn Hotel in Las Vegas, NV from October 7-9, 2015.
BVXV: 3.60 (-0.05)
BiondVax Establishes Capability for the Manufacture of Clinical Grade Universal Flu Vaccine for Phase III Clinical Trials
PR Newswire - Thu Oct 01, 6:00AM CDT
BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV, TASE: BVXV) announced today that it has entered into a Development and Manufacturing Agreement for the production of clinical batches of its universal flu vaccine, M-001, with Cytovance Biologics Inc., a Contract Manufacturing Organization (CMO), based in Oklahoma, USA.
BVXV: 3.60 (-0.05)
BiondVax Initiates a Phase IIb Clinical Trial in Europe for its Universal Flu Vaccine for Pandemic Outbreak
PR Newswire - Wed Sep 30, 6:00AM CDT
BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV, TASE: BVXV) announced today that it received regulatory clearance from the Hungarian Regulatory Authority (National Institute of Pharmacology and Nutrition, OGYEI) and the Central Ethics Committee in Budapest to initiate a Phase IIb clinical trial. The initiation meeting was scheduled for today, September 30, 2015, together with the partners from the UNISEC European Consortium.
BVXV: 3.60 (-0.05)
BiondVax to Present on September 10 at the Rodman & Renshaw Global Investment Conference
PR Newswire - Tue Sep 08, 12:00AM CDT
BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV, TASE: BVXV) today announced that the Company's CEO, Dr. Ron Babecoff, will participate in the Rodman & Renshaw 17th Annual Global Investment Conference, taking place at the St. Regis hotel in New York from September 8-10, 2015.
BVXV: 3.60 (-0.05)
Professor Shai Ashkenazi Appointed to BiondVax's Scientific Advisory Board
PR Newswire - Wed Sep 07, 8:00AM CDT
BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV, TASE: BVXV), a clinical stage biopharmaceutical company focused on developing and commercializing a vaccine against current and future seasonal and pandemic influenza strains, is pleased to announce the appointment of Professor Shai Ashkenazi to its Scientific Advisory Board (SAB).
BVXV: 3.60 (-0.05)
BiondVax Announces Second Quarter 2016 Financial Results and Update
PR Newswire - Thu Aug 18, 3:07PM CDT
BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV; TASE: BVXV), a clinical stage biopharmaceutical company focused on developing and commercializing a vaccine against current and future seasonal and pandemic influenza strains, today announced its second quarter 2016 financial results ended June 30, 2016 and provided a business update.
BVXV: 3.60 (-0.05)
BiondVax Invited to WHO Influenza Vaccine Meeting
PR Newswire - Wed Aug 10, 7:00AM CDT
BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV, TASE: BVXV) today announced that it has been invited to participate in the 'Eighth WHO meeting on the development of influenza vaccines that induce broadly protective and long-lasting immune responses'. The meeting will be held in Chicago, IL on August 23 and 24, 2016.
BVXV: 3.60 (-0.05)
BiondVax CEO to Present Universal Flu Vaccine Technology at BIO International Convention
PR Newswire - Thu Jun 02, 7:17AM CDT
BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV, TASE: BVXV) announced today that BiondVax's CEO, Dr. Ron Babecoff, will be presenting and participating in a panel discussion at BIO International Convention in San Francisco.
BVXV: 3.60 (-0.05)
BiondVax Announces First Quarter 2016 Financial Results and Update
PR Newswire - Tue May 31, 3:01PM CDT
BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV, TASE: BVXV), a clinical stage biopharmaceutical company focused on developing and commercializing immunomodulation therapies for infectious diseases today announced its first quarter 2016 financial results ended March 31, 2016 and provided a business update. The Company's leading product, M-001, is a universal flu vaccine.
BVXV: 3.60 (-0.05)
BiondVax to Present Tomorrow at Joseph Gunner Pioneers 2016 Conference
PR Newswire - Wed May 04, 8:29AM CDT
BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV, TASE: BVXV) announced today that BiondVax's CEO, Dr. Ron Babecoff, will be attending the Joseph Gunnar Pioneers 2016 conference in New York City.
BVXV: 3.60 (-0.05)
BiondVax Announces Fourth Quarter and Full Year 2015 Financial Results and Update
PR Newswire - Wed Apr 27, 4:18PM CDT
BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV, TASE: BVXV), a clinical stage biopharmaceutical company focused on developing and commercializing immunomodulation therapies for infectious diseases, today announced its fourth quarter and full year financial results ended December 31, 2015 and provided a business update.
BVXV: 3.60 (-0.05)
Biondvax's Universal Flu Vaccine Receives Additional US Patent
PR Newswire - Wed Jan 27, 6:00AM CST
BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV, TASE: BVXV) developer of a Universal Flu Vaccine currently undergoing late-stage 2 clinical trials, announced today that its patent application in the United States titled "Multimeric Multi-Epitope Polypeptides in Improved Seasonal and Pandemic Influenza Vaccines" has completed examination and is allowed for issuance as a patent.
BVXV: 3.60 (-0.05)
BiondVax Receives Approval for a Patent for its Universal Flu Vaccine in Israel
PR Newswire - Mon Dec 21, 7:04AM CST
BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV, TASE: BVXV) which is developing the Universal Flu Vaccine, announced today that its patent application in Israel on the Multimeric Multi-Epitope Polypeptide Influenza Vaccines (a universal flu vaccine), was accepted.
BVXV: 3.60 (-0.05)
BiondVax to Bring Long-Awaited Universal Flu Vaccine to the Market
CNW Group - Thu Dec 03, 9:00AM CST
With various advancements being made in preventative care, cancer treatment, HIV and AIDS research and aging, it's hard to believe that the flu is still a serious health threat. However, influenza, an acute respiratory tract infection, can still prove life threatening for the elderly and those with weak immune systems. A common misconception is that influenza is merely a bad cold. Yet, while the flu may produce similar symptoms to the common cold like coughing or nasal congestion, the World Health Organization reports that 250,000 to 500,000 individuals die annually due to the flu, with the majority of those deaths caused pulmonary and cardiovascular complications. Every year, 36,000 people die in the United States and more than 200,000 are hospitalized due to the flu, along with an annual economic burden of over $25 billion.
BVXV: 3.60 (-0.05)
Patent Approval for BiondVax: BiondVax Receives Approval for Patent in Korea for its Universal Flu Vaccine
PR Newswire - Tue Nov 17, 7:54AM CST
BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV, TASE: BVXV) which is developing the Universal Flu Vaccine, announced today that its main patent on the Multimeric Multi-Epitope Polypeptide Influenza Vaccines family, was granted in Korea.
BVXV: 3.60 (-0.05)
BiondVax Announces Third Quarter 2015 Financial Results and Update
PR Newswire - Mon Nov 09, 6:00AM CST
BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV, TASE: BVXV), a clinical stage biopharmaceutical company focused on developing and commercializing immunomodulation therapies for infectious diseases, today announced its financial results for the third quarter of 2015 and provided a business update.
BVXV: 3.60 (-0.05)
BiondVax Pharmaceuticals Ltd. Selects Cytovance(R) Biologics Inc. for the Manufacturing of M-001 the Universal Flu Vaccine for Phase III Clinical Trials
Marketwired - Tue Nov 03, 4:00AM CST
Cytovance® Biologics, Inc. announced that it has entered into a Development and Manufacturing Agreement for the production of Phase III batches of a universal flu vaccine, M-001, with BiondVax Pharmaceuticals Ltd. (TASE: BVXV) (NASDAQ: BVXV), a biopharmaceutical company, based in Ness Ziona Israel.
BVXV: 3.60 (-0.05)
BiondVax Announces Successful Recruitment of the First Participants in a Phase IIb Clinical Trial in Europe with its Universal Flu Vaccine: Multimeric M-001
PR Newswire - Wed Oct 21, 6:59AM CDT
BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV, TASE: BVXV) announced today that it has successfully recruited the first two participants in this trial, BVX-007. The trial is being conducted in Budapest, Hungary at the St Istvan and St Lazslo Hospital, as well as additional satellite sites in Hungary, together with the partners from the UNISEC European Consortium.
BVXV: 3.60 (-0.05)
BiondVax to Present on October 8 at the Aegis Growth Conference
PR Newswire - Tue Oct 06, 3:30PM CDT
BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV, TASE: BVXV) announced today that BiondVax's CEO, Dr. Ron Babecoff, will participate in the Aegis Growth Conference, taking place at The Encore at Wynn Hotel in Las Vegas, NV from October 7-9, 2015.
BVXV: 3.60 (-0.05)
BiondVax Establishes Capability for the Manufacture of Clinical Grade Universal Flu Vaccine for Phase III Clinical Trials
PR Newswire - Thu Oct 01, 6:00AM CDT
BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV, TASE: BVXV) announced today that it has entered into a Development and Manufacturing Agreement for the production of clinical batches of its universal flu vaccine, M-001, with Cytovance Biologics Inc., a Contract Manufacturing Organization (CMO), based in Oklahoma, USA.
BVXV: 3.60 (-0.05)
BiondVax Initiates a Phase IIb Clinical Trial in Europe for its Universal Flu Vaccine for Pandemic Outbreak
PR Newswire - Wed Sep 30, 6:00AM CDT
BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV, TASE: BVXV) announced today that it received regulatory clearance from the Hungarian Regulatory Authority (National Institute of Pharmacology and Nutrition, OGYEI) and the Central Ethics Committee in Budapest to initiate a Phase IIb clinical trial. The initiation meeting was scheduled for today, September 30, 2015, together with the partners from the UNISEC European Consortium.
BVXV: 3.60 (-0.05)
BiondVax to Present on September 10 at the Rodman & Renshaw Global Investment Conference
PR Newswire - Tue Sep 08, 12:00AM CDT
BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV, TASE: BVXV) today announced that the Company's CEO, Dr. Ron Babecoff, will participate in the Rodman & Renshaw 17th Annual Global Investment Conference, taking place at the St. Regis hotel in New York from September 8-10, 2015.
BVXV: 3.60 (-0.05)
